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Advanced HF affects 10% of the HF population and is associated with a dismal quality of life, recurrent hospitalizations, and a mortality of up to 50% at 1 year. 1 -4 Medical arms in left ventricular assist device (LVAD) trials have generally been inotropedependent and have had 1-year mortalities of over 75%. 5, 6 Heart transplantation (HTx) is associated with nearly 90% 1-year survival, 60% 10-year survival, and 95% freedom from symptoms and activity limitations in survivors throughout the follow-up. 7 But because of organ shortage and long waiting times, 10% of transplant listed patients die each year, 8 
Left ventricular assist devices
First generation positive displacement pulsatile LVADs best mimic natural conditions but second generation continuous flow pumps have smaller size, simpler implantation, more limited blood contacting area, fewer moving parts and lack valves, air vents and compliance chambers, providing for longer durability with reduced risks for thromboembolism, infection, and malfunction. Third generation devices utilize impeller or centrifugal motors that are mechanically, magnetically, or hydro-suspended. The sophisticated motor and suspension features minimize complications and allow support for many years and potentially decades, 9 further expanding the candidate pool for LVAD therapy. Current estimates of the number of LVAD candidates range from 10 000 3 to 200 000 10, 11 patients in the USA. These patients would benefit both in terms of prolonged survival and improved symptoms and quality of life. Cost-effectiveness is reasonable at US $36 000-86 000 per life year or quality-adjusted life year in broad populations. 12 Left ventricular assist device therapy receives a class IIa level C for BTT and class IIb level C for DT from the ESC 13 and class IIa level B for DT from ACC/AHA. 14 As technology and long-term outcomes continue to improve, there is indeed potential for LVAD therapy to replace transplantation. All patients with New York Heart Association (NYHA) class III -IV/stage D HF are now potential candidates for LVAD support, but risks and benefits will vary considerably between patients. Thus, knowledge among cardiologists and early referral to transplant/LVAD centres are critical. Favourable outcomes require proper patient selection and strategic timing of implantation and an LVAD programme with a multi-disciplinary team of cardiologists, cardiac surgeons, anaesthetists, perfusionists, nurses, social workers, and other professionals with knowledge of the numerous complex patient-and device-specific aspects before, during, and after implantation.
Indications and contraindications for left ventricular assist devices
Cardiac surgeons and HF specialists are continually improving candidate selection for LVAD support. Previously, patients with chronic HF in NYHA class IV and impending cardiogenic shock and/or multi-organ failure 3,15 -18 were the main candidates for long-term LVAD. However, with improving device technology, surgical skill, and patient management, we are moving toward implantation in a less ill patient cohort. About 80 -90% of LVADs are implanted in transplant candidates who are not expected to survive until transplant or who are deemed too sick for transplant or with potentially reversible transplant contraindications (BTT). 19, 20 Destination therapy is for selected patients who are not eligible for HTx, either due to age or comorbidities, for whom pump therapy is meant to be a permanent, life-long, form of left ventricular replacement. The DT population represents a growing share of implants and offers the greatest potential for improvements in HF morbidity and mortality. For some individuals, the candidacy dichotomization is not clear, either for medical or social reasons, and the term 'bridge to decision' has been applied. Finally, BTR is offered for rare patients where LVAD unloading is expected to lead to sufficient reverse remodelling for clinical recovery and the possibility of explantation. However, the above patient labels are increasingly becoming arbitrary. Up to 17% of DT patients subsequently undergo HTx 4 and many BTT patients subsequently become ineligible for HTx. Recovery is possible but highly unpredictable. 21 -24 Some patients have the LVAD explanted despite incomplete recovery because of device-related complications. The risk prediction tools and criteria for HTx-listing, including the peak VO 2 and the Heart Failure Survival Score (HFSS), are well validated and generally agreed upon. 13,25 -27 In contrast, there are no validated selection criteria and indeed no consensus when it comes to candidate selection for LVAD, and selection relies instead on clinical status, inotrope dependence, and invasive haemodynamic parameters. 3,5,6,15 -18,28 -33 With worsening clinical status, the need for LVAD increases but so does the peri-operative risk, and optimal operative timing becomes difficult (see what follows).
The main goals of LVAD therapy are to improve symptoms, quality of life, and prognosis. But other important goals are to stabilize or reverse organ dysfunction or pulmonary vascular hypertension to increase the likelihood of a successful transplant, to prevent progressive right ventricular dysfunction which would make a future LVAD high risk or contraindicated, or to provide early unloading to prevent remodelling in a cardiomyopathy with hopes for recovery. Expected waiting time for HTx, which are highly variable between different regions and dependent on body size, blood type and panel reactive antibodies, as well as local conditions with regard to types of devices available, practice and expertise, regulation and ethical views also play important roles and make decisions to and timing of implant difficult. 34 Risks and benefits may be difficult for patients to grasp. Patient preferences are highly variable but in one study LVAD implantation was preferred if life expectancy without LVAD was 6-12 months or less and activity was limited to less than one block walking. 35 This level of severity is similar to that where most clinicians would recommend LVAD implantation ( Table 1 ). The urgency of acute implantation and/or bridging from short-term mechanical support often preclude a complete medical and psychosocial assessment, but discontinuation of device support due to undetected conditions is rare and outcomes are similar to elective implantations with complete pre-operative assessments. 36 An Table 2) . Table 1 describes these authors' proposed indications and contraindications for LVAD therapy, derived from international consensus and entry criteria in clinical studies. 3,5,6,15 -18,28 -33,39,40 Outcomes after left ventricular assist device
Outcomes after LVAD placement are dependent on the era of implant, surgical experience, device and patient characteristics, and time after implant. Operative mortality in well-selected patients has improved to about 5-10%; 30, 41 survival to transplant has improved from 33 to 71% in one series; 29 and 1-year overall survival has improved from about 50% 5, 6, 19 to nearly 80%. 20, 28, 30, 42, 43 The peri-operative period is crucial, with the vast majority of deaths occurring prior to hospital discharge. 4 The most important complications peri-operatively are multi-organ failure, neurologic or peripheral embolic events, bleeding, infection and sepsis, and acute RV failure (see what follows). 44, 45 In the longer term, complications include embolic or haemorrhagic stroke, the progression of preexisting or de novo development of RV failure, human leucocyte antigen (HLA) sensitization, renal insufficiency, device failure or infection requiring transplantation, explantation or replacement, gastrointestinal bleeding, and psychological maladjustment. 6,19,28 -30,39,45,46 Left ventricular unloading generally improves sustained ventricular arrhythmia burden, but a short-term increase in arrhythmias has been documented. 47, 48 54 and shorter duration of intensive care, 51 but possibly more risk of thromboembolism 54 than older pulsatile devices. 5, 6, 29 One-year survival in subjects undergoing
HeartMate XVE (Thoratec Corporation, Pleasanton, CA, USA) implantation for DT in the REMATCH trial was 52%. 5 While the patient cohort was different and interpretation is more difficult The HeartMate VE or XVE has now been implanted in more than 5000 patients. 55 The importance of experience was illustrated in REMATCH, where patients in the LVAD group enrolled in 1998-99 had 44% 1-year and 21% 2-year survival, respectively, compared with 59 and 38% for those enrolled in 2000-01. 56 In a post-REMATCH DT cohort with HeartMate XVE (Thoratec), 1-year survival was 62%.
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Selection and risk scores with focus on overall outcomes
The most important factor for improving patient outcomes after LVAD is careful patient selection. In addition, there are several risk scores that predict overall outcomes ( Table 3 ). The Lietz-Miller destination therapy risk score (DTRS) analysed 45 baseline parameters and outcomes in DT patients in the post-REMATCH era. Laboratory, haemodynamic, and clinical predictors generated a score that divided candidates into low-, medium-, and high-risk strata. 4 Klotz et al. 68 analysed 100
pre-operative parameters in a variety of device recipients and found 34 univariate and 13 multi-variate risk factors for intensive care unit mortality. They devised a score with high-, medium-, and low-risk strata. The Columbia University/Cleveland Clinic risk factor selection scale (RFSS) 62 and revised screening scale (RSS) 63 analysed predictors in BTT recipients, and Holman et al. 67 in the INTERMACS database.
These studies and risk models have several important limitations. They were derived mainly in patients receiving first generation pulsatile devices; they do not consider under-represented populations such as women, African Americans, and those who due to body size limitations were ineligible for the larger first generation devices. Comorbidities such as diabetes or severe cachexia or obesity were under-represented but have theoretical reasons to fare worse and may preclude transplant. Psychosocial factors and outcomes are not considered. Recidivism of drug and/or alcohol and return to work are unknown. Finally, data are available only on short-term and not longer term outcomes.
Importantly, these models also lack prospective independent validation. We dichotomized 145 LVAD recipients according to published thresholds for several scores and observed hazard ratios for 6-month death, renal failure, and RVAD need ranging from 2.1 to 9.4 when comparing high-to low-risk strata and positive and negative predictive values for death ranging from 23 to 43% and 88 to 91%, respectively. 87 Thus, another major limitation is that while low-risk patients identified by the models are likely low risk, patients with high-risk scores are not necessarily truly high risk. As we move toward less ill patients, these scores will need re-evaluation.
Selection and risk scores with focus on right ventricular failure
In the long term, LV unloading and decreases in LV filling pressures and subsequently pulmonary vascular resistance (PVR) often lead Rao et al. 63 Lietz et al. 4 Holman et al. 67 Klotz et al. to improved RV function after LVAD. But in the early postoperative period, numerous complex mechanisms may contribute to RV failure. These include sudden increases in cardiac output, leading to increased venous return and thus RV preload, septal shift causing increased RV wall stress, and increased pulmonary vasoreactivity in the setting of cardiopulmonary bypass, blood transfusions, and inflammation, leading to increased RV afterload. 65 The incidence of RV failure ranges from 7 to 50% depending on definition and study. 17 -19,64 -66,69,71,72 Right ventricular failure leads to liver and renal failure, lymphoedema and ascites, and underfilling of the LV and the pump, with potential for arrhythmia and cardiogenic shock. Peri-operative mortality increases from 19 to 43% and survival both to and after HTx becomes worse, 65 although it has been suggested that increased risk is primarily in the peri-operative period and that chronic RV failure post LVAD may not impair successful bridging to transplantation. 88 The impact of long-term LVAD support on RV function and the intrinsic progression of RV cardiomyopathy warrants study and may be an obstacle in the era of 'permanent' LVAD support. There is limited prospective data but anecdotal evidence suggests that the risk of RV failure can be decreased by pre-operative optimization of nutrition, haemodynamics, and organ function and minimization of RV pre-load, with parenteral nutrition, inotropes, and intra-aortic balloon pump (IABP). Other steps to lower the risk of RV failure include peri-operative minimization of bleeding and transfusion needs, effective coronary perfusion and avoidance of cardioplegia, avoidance of surgical RV injury and RV distension, prophylactic RVAD 89, 90 and inotropes, tricuspid annuloplasty, early cessation of positive pressure ventilation and RV afterload reduction with nitric oxide 18,91 nitroprusside, and perhaps prostanoids, endothelin receptor antagonists and phosphodiesterase inhibitors. Nonetheless, escalating inotropic therapy and therapeutic mechanical RV assist often become necessary. Most important, again, is careful selection. For those accustomed to HTx selection, assessing RV failure risk post LVAD is counterintuitive. A key favourable prognostic factor is the ability of the RV to generate pressure and forward flow; thus high pulmonary artery pressure (PAP) is favourable, whereas high central venous pressure (CVP) and pre-operative RV failure and large tricuspid regurgitation are detrimental. We identified vasopressor requirement, aspartate aminotransferase !80 IU/L, bilirubin ! 2.0 mg/dL, and creatinine ! 2.3 mg/dL as independent predictors or RV failure and constructed an RV failure risk score with an area under the receiver-operating characteristic curve of 0.73. , creatinine !1.9 mg/dL, severe pre-operative RV dysfunction and previous cardiac surgery as independent risk factors and constructed an algorithm for predicting RVAD need with .80% sensitivity and specificity. Numerous additional predictors have been identified, many of which directly or indirectly reflect RV function ( Table 4) . 64 -66,69,71 -73,76,78,79,92 More severe INTERMACS patient profiles more often have biventricular failure and markers of RV failure such as liver dysfunction and ascites, are more likely to require BiVAD or TAH, and have worse outcomes. 81, 93 Interpretation of these data is clouded by the fact that most publications identified only univariate predictors and describe exclusively 18,39,69,71 -73,76,78,92 or mostly first generation devices. 19, 65 Although RV failure appears less common with second generation devices, 28, 30 there are also fewer parameters to predict it. 94 
Timing of implantation
With limited data to suggest otherwise, many clinicians implant LV support only when patients are severely ill ( Table 1) . But longer durability and fewer complications with modern devices as well as recognition of the unpredictability of HF deterioration and the importance of being in good clinical and RV status has lead to a shift toward less catastrophically ill patients, such as INTERMACS 3 -4 or prior to chronic inotrope dependence. Up to 40% of stable HTx listed patients destabilize to require high-urgency HTx or emergency LVAD. 95 Earlier implantation, before RV and multiorgan failure, leads to better outcomes (see under risk scores above). This is a favoured strategy for DT. Yet, LVADs are still associated with 5-10% peri-operative mortality 30, 41 and considerable morbidity and cost, and a HTx-listed patient in good clinical status and a short estimated waiting time may be better served by conservative management. An emerging issue in BTT patients is whether to implant an LVAD before the institution of chronic inotrope support, a decision that depends on the relative effects of inotropes and LVADs on survival up to and after HTx. Survival on the waiting list depends on the likelihood of being transplanted within a reasonable time. 34 A vast majority of patients implanted to date have been inotropedependent. 5,6,17,19,28 -30,39,45,46,96 The most important factor in improving outcomes is proper selection. Selecting patients for LVAD will require a comprehensive assessment of indications and contraindications (Table 1) , risk factors, and scores for overall outcomes ( Table 3 ) and outcomes with regard to RV failure (Table 4) , as well as optimal timing.
However, LVADs are still associated with an approximately 5 -10% peri-operative mortality and frequent short-and long-term complications including right ventricular failure, bleeding, thromboembolic and haemorrhagic stroke, infection, and device failure.
Improved technology, experience, and patient selection have improved outcomes, but also make published risk prediction studies obsolete. Thus, more prospective multicentre studies are needed to assess risk in a broad range of subjects undergoing LVAD implantation. Furthermore, as we embark on an era of true long-term support, more studies are needed to predict longterm outcomes. Bold denotes independent predictors of RV failure post-LVAD implantation, generally defined as need for RVAD or prolonged inotropic support. Some studies have identified univariate predictors. 71 -73,75,77,78,92 Others have performed multivariate analysis and identified both univariate and independent predictors. 64 -66,69,74,76 Italics denotes specific cut-offs in continuous variables for high risk. Some studies have simply identified significant differences in the variables between RV failure and non-RV failure groups; 69,71 -76,78,92 for these, only a qualitative statement ('high' or 'low') is possible. Others have identified specific cut-offs for elevated risk. 64 -66,77 TIA, transient ischaemic attack; CVA, cerebrovascular accident; IABP, intra-aortic balloon pump; SAPS II, New Simplified Acute Physiology Score; 104 BUN, blood urea nitrogen; NT-proBNP, N-terminal pro-brain natriuretic peptide; RVSWI, right ventricular stroke work index ¼ (mPAP 2 mRAP) Â CI Â 1000/heart rate; sPAP, systolic pulmonary artery pressure; mPAP, mean pulmonary artery pressure; dPAP, diastolic pulmonary artery pressure; TPG, transpulmonary gradient; PVR, pulmonary vascular resistance; CVP, central venous pressure; PCWP, pulmonary capillary wedge pressure; SVO 2 , mixed venous O 2 saturation; CI, cardiac index; CO, cardiac output; SVR, systemic vascular resistance; SBP, systolic BP; MAP, mean BP; DBP, diastolic BP; TR, tricuspid regurgitation; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion; RVEDV, RV end-diastolic volume; RVESV, RV end-systolic volume. a Conflicting data in the literature.
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